NYSE:ASHChemicals
Ashland (ASH) Could Be 6% Undervalued On New Oral Biologics Launch
Ashland (ASH) is drawing fresh attention after launching permexa sodium caprate, an excipient aimed at oral peptide and biologic drugs, including GLP-1 programs, with investors watching how this product could influence its future commercial traction.
Ashland’s launch of permexa sodium caprate and its upcoming Innovation Day on 17 September 2026 arrive alongside a 32.7% 90 day share price return and 41.7% 1 year total shareholder return, which indicates recent momentum in the stock.
Scan 19...